Related Experiment Video
Updated: Apr 1, 2026
07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
1.3K
Characterizing nerve growth factor-p75(NTR) interactions and small molecule inhibition using surface plasmon
Kristen S A Sheffield1, Allison E Kennedy2, John A Scott3
1Department of Biology, Laurentian University, Sudbury, Ontario P3E 2C6, Canada.
Analytical Biochemistry
|October 6, 2015
Summary
Small molecule inhibitors targeting nerve growth factor (NGF) interactions with its receptors are crucial for treating neurodegenerative diseases and pain. This study reveals PD90780 selectively inhibits NGF binding to the p75(NTR) receptor.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Nerve growth factor (NGF) is vital for neuronal health, regulating proliferation, differentiation, and survival via p75(NTR) and TrkA receptors.
- Dysregulated NGF signaling is linked to neurodegeneration (e.g., Parkinson's, Alzheimer's) and pain states, highlighting therapeutic potential for NGF antagonists.
- Existing small molecule antagonists (ALE-0540, PD90780, Ro 08-2750, PQC 083) inhibit NGF-TrkA interaction, but their effect on NGF-p75(NTR) binding remains uncharacterized.
Purpose of the Study:
- To characterize the binding of NGF to the p75(NTR) receptor.
- To evaluate the inhibitory potential of known NGF antagonists on NGF-p75(NTR) interactions.
- To assess receptor selectivity among these NGF inhibitors using surface plasmon resonance (SPR).
Main Methods:
- Utilized SPR biosensors to analyze NGF binding kinetics to immobilized p75(NTR).
- Screened known NGF antagonists (ALE-0540, PD90780, Ro 08-2750, PQC 083) for their ability to inhibit NGF-p75(NTR) complex formation.
- SPR analysis provided quantitative data on binding affinities and inhibition constants.
Main Results:
- Successfully characterized NGF binding to the p75(NTR) receptor using SPR.
- Demonstrated that only PD90780 effectively inhibited NGF binding to the p75(NTR) receptor.
- ALE-0540, Ro 08-2750, and PQC 083 did not show significant inhibition of NGF-p75(NTR) interaction under the tested conditions.
Conclusions:
- This study provides the first evaluation of small molecule antagonists' ability to block NGF binding to the p75(NTR) receptor.
- PD90780 exhibits selectivity, inhibiting NGF interaction with p75(NTR) while other tested compounds do not.
- Findings suggest potential for developing selective NGF pathway modulators for therapeutic applications in neurological disorders and pain management.
